Technical Analysis for UTHR - United Therapeutics Corporation

Grade Last Price % Change Price Change
grade B 115.75 1.37% 1.56
UTHR closed up 1.37 percent on Friday, January 18, 2019, on 81 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Flat Up Up
See historical UTHR trend table...

Date Alert Name Type % Chg
Jan 18 Narrow Range Bar Range Contraction 0.00%
Jan 18 NR7 Range Contraction 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.37%
Jan 17 Overbought Stochastic Strength 1.37%
Jan 16 Bearish Engulfing Bearish 1.87%
Jan 16 Outside Day Range Expansion 1.87%
Jan 16 Overbought Stochastic Strength 1.87%
Jan 15 Doji - Bearish? Reversal 0.70%
Jan 15 Outside Day Range Expansion 0.70%

Older signals for UTHR ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
United Therapeutics Corporation, a biotechnology company, focuses on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product is Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops oral treprostinil, an orally delivered prostacyclin analog for treatment of pulmonary hypertension; Ch14.18 MAb, an antibody in Phase III clinical trials for the treatment of neuroblastoma; Beraprost 314d, which is entering Phase III clinical trails for the treatment of PAH; PLacental eXpanded cells, which are entering a Phase I trial for the treatment of PAH; and 8H9 MAb, an antibody that is under Phase I clinical trial for the treatment of metastatic brain cancer. Further, the company is involved in the pre-clinical stage of developing TransCon Treprostinil, TransCon Beraprost, and glycobiological antiviral agents for the treatment of infectious diseases, such as Hepatitis C; and engineered lungs and lung tissue, which can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Is UTHR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 143.73
52 Week Low 100.06
Average Volume 360,392
200-Day Moving Average 116.3125
50-Day Moving Average 112.0248
20-Day Moving Average 110.076
10-Day Moving Average 114.238
Average True Range 3.3601
ADX 19.71
+DI 19.1277
-DI 13.2996
Chandelier Exit (Long, 3 ATRs ) 106.1497
Chandelier Exit (Short, 3 ATRs ) 110.1403
Upper Bollinger Band 119.5324
Lower Bollinger Band 100.6196
Percent B (%b) 0.8
BandWidth 17.181584
MACD Line 1.2151
MACD Signal Line 0.4252
MACD Histogram 0.7899
Fundamentals Value
Market Cap 5.03 Billion
Num Shares 43.5 Million
EPS 8.62
Price-to-Earnings (P/E) Ratio 13.43
Price-to-Sales 3.17
Price-to-Book 2.91
PEG Ratio -0.38
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 118.05
Resistance 3 (R3) 117.81 116.82 117.66
Resistance 2 (R2) 116.82 116.23 116.93 117.53
Resistance 1 (R1) 116.28 115.87 116.55 116.52 117.41
Pivot Point 115.29 115.29 115.42 115.40 115.29
Support 1 (S1) 114.75 114.70 115.02 114.99 114.09
Support 2 (S2) 113.76 114.34 113.87 113.97
Support 3 (S3) 113.22 113.76 113.84
Support 4 (S4) 113.46